Abstract. Epithelial cell adhesion molecule (EpCAM), involved in Ca
Introduction
Oral squamous cell carcinoma (OSCC) is the most frequent cancer of the head and neck (1,2) with surgery, radiation, and chemotherapy being the standard treatments. Despite therapeutic advances, functional disorders after surgery often occur. Although many studies investigating molecular targets as markers to determine the prognosis of patients have been developed, further functional analyses are required to develop therapies for oral cancer (3) (4) (5) .
In independent studies, epithelial cell adhesion molecule (EpCAM) has been observed to be expressed in several carcinomas (6) (7) (8) (9) (10) (11) . It is a 34-42-kDa transmembrane protein mediating Ca 2+ -independent homotypic cell-cell adhesion in epithelial cells (12) , and does not belong to the four major adhesion molecule families (cadherins, integrins, selectins, and the immunoglobulin superfamily) (13, 14) . EpCAM consists of an extracellular domain of 265 amino acids including two epidermal growth factor (EGF)-like repeats, a transmembrane domain of 23 amino acids and a short intracellular domain of 26 amino acids (15) (16) (17) . Expression is restricted to the basolateral membrane of the majority of epithelium tissue, except in adult squamous epithelium and several specific epithelia (12, 17, 18) . EpCAM has been shown to be overexpressed in several carcinomas including colon, lung, stomach, prostate, cervical, and breast cancer (19) (20) (21) (22) . Furthermore, the expression level of EpCAM reportedly correlates with cell proliferation and invasiveness of cancers including oral cancer, indicating EpCAM could be an efficient molecular target (19, 21, 23) . Clinical studies investgating the efficacy of the monoclonal antibody, catumaxomab, in non-small cell lung cancer and ovarian cancer has indicated the efficacy of targeting EpCAM (24, 25) .
Cyclin D1 is an important regulator through the G1 phase of the cell cycle, and it forms a cyclin-dependent kinase (CDK) complex by binding Cdk4 and Cdk6 (26) . Through phosphorylation and deactivation of retinoblastoma protein by the complex, the E2F transcription factor activates several genes required for advancement from the G1 into the S phase (27) . Uncontrolled cell proliferation is a characteristic of cancer, and high levels of cyclin D1 expression promotes cell growth and malignancy of several cancer types (28) (29) (30) (31) .
Here we determined that EpCAM expression upregulated or maintained the cell cycle regulator, cyclin D1 in oral cancer cell lines as multicellular aggregates (MCAs). Adult mice. Adult mice (3-6 weeks old; ICR male and female; Japan SLC, Inc., Shizuoka, Japan) were maintained according to the institutional guidelines of the Research Institute for Microbial Diseases, Osaka University. The mice were used for RNA isolation from testis, kidney, liver, brain, intestine, stomach, heart, lung, tongue, and ovary.
Materials and methods

Cell
RT-PCR.
Total RNA was isolated with TRIzol (Invitrogen) from cultured cells and tissues of the adult mice. cDNA was synthesized using Random Primer 6 (New England BioLabs, Ipswich, MA) and SuperScript™Ⅲ Reverse Transcriptase (Invitrogen). cDNA was amplified by Takara Ex Taq ® Hot Start Version (Takara Biotechnology, Shiga, Japan) for PCR analysis. Primer sequences for PCR were EpCAM (Fw, 5'-GA ATGGCTCAAAACTTGGGA; Rv, 5'-ACGCGTTGTGATC TCCTTCT), Cyclin D1 (Fw, 5'-CCCTCGGTGTCCTACTTCA; Rv, 5'-GTTTGTTCTCCTCCGCCTCT), GAPDH (Fw, 5'-ACA GTCAGCCGCATCTTCTT; Rv, 5'-TGGAAGATGGTGATGG GATT), mEpCAM (Fw, 5'-ATGGACCTGAGAGT GAACGG; Rv, 5'-CACGGCTAGGCATTAAGCTC), mGapdh (Fw, 5'-CC CACTAACATCAAATGGGG; Rv, 5'-CCTTCCACAATGCCA AAGTT). Quantification of band intensities were performed with LAS4000 mini (Fujifilm, Osaka, Japan). Expression levels of each sample were normalized against GAPDH mRNA expression. Cell proliferation assay. Proliferation of siRNA transfected cells after incubation for 0, 24, 48, or 96 h in 96-well plates was assessed using the MTT assay (CellTitler 96 ® Non-Radioactive Cell Proliferation Assay; Promega, Tokyo, Japan) according to the manufacturer's instructions. The absorbance at 570 nm was measured using a 96-well plate reader (Labsystems Multiskan MS-UV; Labsystems, Helsinki, Finland).
RNA interference (RNAi
Immunofluorescence staining. MCA cultures of HSC-4 cells were fixed with 3.5% formaldehyde, permeabilized with 0.2% Triton X-100, and blocked with Image-iT™ FX Signal Enhancer (Invitrogen). Cyclin D1 antibody was used as primary antibody. Next, Alexa488 conjugated IgG (Invitrogen) was used as secondary antibodies. After incubation with the antibodies, SlowFade ® Gold antifade reagent with DAPI (Invitrogen) was added and coverslips mounted. The specimens were observed using an immunofluorescence microscope (Leica Microsystems Japan, Tokyo, Japan).
Statistical analysis.
A Mann-Whitney U test was performed using StatView 5.0 (Abacus Concepts Inc., Berkeley, CA) to assess the statistically significance difference between samples. Data are presented as the mean ± SD. P-values < 0.05 were considered statistically significant.
Results
EpCAM expression associates with oncogenesis in the tongue.
To confirm the association of EpCAM expression with oncogenesis in the tongue, we analyzed EpCAM mRNA levels in mouse tissues and human oral cancer cell lines using RT-PCR. EpCAM mRNA was clearly detected in testis, kidney, intestine, and lung of mice, and faintly in the tongue and ovary (Fig. 1A) . In oral cancer cell lines derived from tongue, EpCAM mRNA was strongly detectable in SAS and HSC-4 cells and weakly in HSC-3 (Fig. 1B) , indicating that the expression levels of EpCAM were different depending on the locus of derived tissues and differentiation of cells. These data suggest that EpCAM expression associates with carciogenesis in the tongue.
Effects of downregulation of EpCAM in oral cancer cell lines as monolayers.
Previous studies suggest that EpCAM is related to the prolifration and invasion of cancer cells (19, 21, 23) . To confirm the function of EpCAM on proliferation in oral cancer cell lines as monolayers, EpCAM knockdown in HSC-3 and HSC-4 cells by transient transfection with EpCAM siRNA was performed. EpCAM mRNA levels decreased drastically in the siRNA transfected cells (Fig. 2B and C) . In the control cells transfected with or without scrambled RNA, the expression level of EpCAM was not affected (Fig. 2B and C) . Downregulation of EpCAM did not significantly influence HSC-4 cell proliferation ( Fig. 2A) or cyclin D1 expression (Fig. 2B) . Downregulation of EpCAM in HSC-3 cells did not affect the expression level of cyclin D1 ( Fig. 2C) . These results indicate that EpCAM expression did not impact cell proliferation and cyclin D1 expression level in HSC-3 and HSC-4 cells as monolayers. (Fig. 3A and B) . Data suggest that cell surface EpCAM molecules are not involved with cell aggregation. Cyclin D1 expression in EpCAM downregulated MCAs was significantly repressed (Fig. 3A and C) , indicating that the EpCAM expression could be associated with the cyclin D1 expression in MCAs of HSC-4 cells.
Effects of downregulation of EpCAM on cyclin D1 level in oral
To examine the localization of cyclin D1 in oral cancer cell lines as MCAs, immunofluorescence staining was performed using cyclin D1-specific antibody. Specific staining was distinctly localized to the nucleus in some cells in control MCAs (Fig. 4A) . On the other hand, nuclear signals of cyclin D1 staining could not be detected in MCAs from HSC4 cell-transfected siRNA for EpCAM (Fig. 4C) . These results show that nuclear restricted cyclin D1 protein localization disappeared in EpCAM eliminated MCAs of HSC4 cells.
Discussion
The expression patterns of EpCAM in normal tissues of mice and in human OSCC cell lines suggest that EpCAM levels increase during carcinogenesis from the tongue and their overexpression was maintained in parts of tumor tissues because its expression is highly conserved between humans and mice (14, 32) . This is consistent with previous studies reporting that EpCAM expression is related to cell proliferation in several cancers through the regulation of specific genes including cell cycle regulators (19, 21, 23, 33) . Although EpCAM did not contribute to cell proliferation in HSC-4 and HSC-3 cells as monolayers, RNAi-mediated downregulation of EpCAM expression reduced the mRNA expression level of cyclin D1 in MCAs and eliminated cyclin D1 protein in nuclei of MCAs. These data indicate that cell proliferation through cyclin D1 expression in HSC-4 cells is regulated by EpCAM under anchorage-independent cell aggregation conditions. Thus, EpCAM plays various roles depending on the environment of the surrounding cells as well as cell types.
EpCAM is known to be a marker of poor prognosis including metastasis in several carcinomas (34) (35) (36) (37) (38) . Metastasis is a multistep process, during which primary tumor cells invade adjacent tissues, intravasate, translocate through the vasculature, arrest in distant capillaries, extravasate into the surrounding tissue, and finally proliferate into second tumors (39) . Metastatic cancer cells need anoikis resistancy and growth ability in single cells and small cell clusters that are anchorage-independent. MCAs represent a culture model of anchorage-independence (40) and HSC-4 cells with or without siRNA treatment for EpCAM exhibited survival in MCAs culture, indicating that HSC-4 cells have the ability of anoikis resistance independent of EpCAM. Thus, EpCAM may assist cancer cells to initiate growth in a small clusters losing anchoradge-dependency in delivery through the lymphatic and circulatory systems or arrest around the target tissue.
EpCAM, one of the most highly and frequently expressed tumor-associated antigens, is found on a wide range of epithelial cancers (22) . Furthermore, EpCAM was identified as a cancer stem cell antigen (41) (42) (43) . It has also been highlighted as a target antigen for cancer immunotherapy, and many antibody-based therapeutic approaches targeting EpCAM are currently in development (44) (45) (46) (47) (48) (49) . Alternatively, the possibility of RNAibased therapeutics has been reported (50) . We successfully applied RNA silencing to inhibit the expression of EpCAM, thereby decreasing cyclin D1 levels in cancer cells. Therefore, we propose the possibility that RNAi-mediated gene silencing of EpCAM may be a useful strategy for treatment of tongue cancer metastasis.
